In consultation: Guidance and quality standards
Showing 1 to 10 of 15
| Title | Consultation | Type | Consultation end date |
|---|---|---|---|
| NICE Funding Variation Request Consultation | Methods / process manual consultation | NICE process and methods | |
| Zongertinib for treating HER2-mutated unresectable or metastatic non-small-cell lung cancer ID6573 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Zanidatamab with chemotherapy with or without tislelizumab for untreated HER2-positive unresectable advanced gastro-oesophageal adenocarcinoma ID6672 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Ex-situ machine perfusion devices to preserve deceased donor livers for transplantation | Draft guidance | Health technology evaluation | |
| Ianalumab for treating active Sjogren's syndrome ID6634 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249] | Draft guidance | Technology appraisal guidance | |
| Nirogacestat for treating desmoid tumours [ID6453] | Draft guidance | Technology appraisal guidance | |
| Modular update to NICE manuals: EQ-5D-5L value set | NICE general consultation | NICE general | |
| Prostate cancer: diagnosis and management (update) | Scoping | NICE guideline | |
| Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6757] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance |